Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label trial of gMSC1 versus intra-articular hyaluronic acid for knee osteoarthritis cartilage defects
jRCT2053260187Phase 3Recruiting
- Sponsor
- Two Cells
- Start
- Sep 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in knee osteoarthritis (OA) and chondral defect comparing gMSC1 implantation with Intra-articular hyaluronic acid (2 arms). Primary endpoints: Structural evaluation of cartilage and Patient-reported symptoms. Started Sep 2026; status: recruiting.
02
Drugs
gMSC1hyaluronic acid
03
Conditions
knee osteoarthritis (OA)chondral defect
Beyond the preview
Go deeper on jRCT2053260187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053260187.